What adjuvant therapy should be added to Lunesta (eszopiclone) for insomnia?

Adjuvant Therapy to Lunesta (Eszopiclone)

The most effective adjuvant therapy to add to Lunesta is cognitive behavioral therapy for insomnia (CBT-I), which should be implemented as the primary adjunctive treatment regardless of whether pharmacotherapy was initiated first.

Primary Recommendation: Add CBT-I

Behavioral and cognitive therapies should supplement hypnotic treatment whenever possible 1. This is a consensus recommendation across all major sleep medicine guidelines. CBT-I includes stimulus control therapy, sleep restriction therapy, cognitive therapy, and relaxation techniques—not just sleep hygiene education alone 1.

Why CBT-I First?

• Sleep hygiene alone is insufficient and must be combined with other behavioral interventions 1
• CBT-I is effective for both primary and comorbid insomnia, including in older adults and chronic hypnotic users 1
• The American College of Physicians (2016) strongly recommends CBT-I as initial treatment, with medications added only through shared decision-making if CBT-I alone is unsuccessful 2

If Additional Pharmacotherapy Is Needed

When Lunesta (eszopiclone) alone with CBT-I proves insufficient, the guidelines provide a clear escalation sequence 1:

Step 1: Try an Alternative BzRA or Ramelteon

• Switch to zolpidem, zaleplon, or ramelteon if eszopiclone response is inadequate
• This addresses the possibility that a different receptor profile may work better for the individual patient

Step 2: Add a Sedating Antidepressant (If Comorbid Depression/Anxiety)

Particularly important if comorbid mood or anxiety disorders are present:

• Trazodone, doxepin (low-dose), mirtazapine, or amitriptyline 1
• Evidence specifically supports eszopiclone combined with escitalopram for comorbid generalized anxiety disorder, showing improved sleep, anxiety, and mood outcomes 3
• Note: Low-dose sedating antidepressants do NOT constitute adequate treatment for major depression—full therapeutic doses of antidepressants are required 1

Step 3: Combine BzRA with Sedating Antidepressant

• This combination approach is recommended when monotherapy with either agent fails 1

Step 4: Consider Other Sedating Agents (For Specific Comorbidities)

• Anti-epileptic medications (gabapentin) or atypical antipsychotics (quetiapine, olanzapine) 1
• These are only suitable for patients with comorbid conditions who may benefit from the primary action of these drugs 1

What NOT to Add

The guidelines are explicit about ineffective or not recommended adjuncts:

• Trazodone as monotherapy: Weak recommendation AGAINST use 4
• OTC antihistamines (diphenhydramine): Not recommended due to lack of efficacy and safety data 1, 4
• Melatonin, valerian, L-tryptophan: Insufficient evidence; not recommended 1, 4
• Tiagabine: Weak recommendation AGAINST use 4

Newer Alternative: Dual Orexin Receptor Antagonists (DORAs)

Recent evidence (2022-2024) suggests that switching from eszopiclone to suvorexant or daridorexant may be beneficial, particularly in patients with comorbid depression 5, 6, 7:

• Suvorexant improved benzodiazepine-unresponsive insomnia in MDD patients 7
• DORAs inhibit wakefulness rather than induce sedation, with no rebound insomnia or withdrawal 6
• Daridorexant can be used to alleviate withdrawal symptoms when tapering benzodiazepine receptor agonists 8

Critical Implementation Points

When adding any adjunctive therapy:

• Follow patients every few weeks initially to assess effectiveness and side effects 1
• Use the lowest effective maintenance dose 1
• Educate patients about treatment goals, safety concerns, potential side effects, drug interactions, and risk of dosage escalation 1
• Collect sleep diary data before and during treatment 1
• Reassess every 6 months due to high relapse rates 1

Common Pitfalls to Avoid

1. Don't prescribe sleep hygiene alone—it must be combined with active behavioral interventions 1
2. Don't use low-dose antidepressants as sole treatment for comorbid major depression—full therapeutic doses are required 1
3. Don't combine eszopiclone with alcohol or other CNS depressants—additive psychomotor impairment 1
4. Don't ignore comorbid conditions—reevaluate for occult disorders if treatment fails 1